Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Health Network, Toronto
With
CIHR Canadian HIV Trials Network
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult (aged 18 years or older or as per Local/Provincial Guidelines)
documented HIV-1 infection (determined by EIA and Western blot, sites' standard assays are acceptable if approved in advance by the PIs for the study, Dr. Darrell Tan and/or Dr. Sharon Walmsley)
no use of chronic anti-HSV therapy for the past 6 months, and not anticipated to require chronic anti-HSV therapy during the study
antiretroviral naïve (no more than 14 days of total prior ARV exposure)
CD4 count within the 400-900 cells/mm3 range (inclusive) on two consecutive occasions, with at least one measurement within 30 days of initiating trial (baseline visit)
does not meet recommendations for initiating ARV therapy according to current guidelines
You may not be if
pregnancy or actively planning to become pregnant
receiving chemotherapy, chronic steroid therapy or other immunomodulatory medications (e.g. interferon, azathioprine, methotrexate, TNF-alpha antagonists, etc.)
Estimated creatinine clearance \<30 mL/min
Other medical condition likely to cause death within 24 months
Enrolled in a therapeutic HIV vaccine or immunotherapy trial
Enrolled in another trial investigating the impact of another intervention on HIV disease progression
HIV elite controller (EC), phenotypically defined here as documented duration of HIV infection of ≥5 years, a persistent CD4 cell count ≥500 cells/mm3, and a persistent plasma HIV viral load of \<1000 copies/mL in the absence of antiretroviral therapy
Clareo Health | Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?
